Genencor to receive patent for I-MUNE assay technology for reduction or enhancement of immune response.(Genencor International)

BIOTECH Patent News, December, 2004

Genencor International (Palo Alto, CA) has been notified a United States patent on its I-MUNE Assay will be granted on December 28, 2004. The assay is a unique method of identifying the components of proteins that induce an immunogenic response. The grant of the United States patent will complement Genencor's previously granted European patent to I-MUNE technology. Information provided by the assay is useful for designing proteins with either enhanced immunogenicity (e.g., for vaccines) or reduced allergenicity (e.g., potential for causing allergic reactions) caused by proteins in a range of industrial and consumer products and many of the increasing number of pharmaceuticals that are made from recombinant proteins. United States Patent 6,835,550 and European Patent...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.